Higher dose weekly fluoxetine in hemodialysis patients: A case series report | Zendy

Kelley Kauffman | Zendy; Jacqueline Dolata | Zendy; Maria Figueroa | Zendy; Douglas D. Gunzler | Zendy; Anne M. Huml | Zendy; Julie Pencak | Zendy; Ashwini R. Sehgal | Zendy; Martha Sajatovic | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Higher dose weekly fluoxetine in hemodialysis patients: A case series report

Author(s) -

Kelley Kauffman,

Jacqueline Dolata,

Maria Figueroa,

Douglas D. Gunzler,

Anne M. Huml,

Julie Pencak,

Ashwini R. Sehgal,

Martha Sajatovic

Publication year - 2020

Publication title -

the international journal of psychiatry in medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.458

H-Index - 55

eISSN - 1541-3527

pISSN - 0091-2174

DOI - 10.1177/0091217420913399

Subject(s) - fluoxetine , hemodialysis , series (stratigraphy) , medicine , biology , receptor , serotonin , paleontology

The antidepressant medication fluoxetine at 90 mg dosed weekly is as effective and safe as standard formulation fluoxetine 20 mg dosed daily in patients with major depressive disorder. Weekly fluoxetine has not been well studied in hemodialysis patients, and doses beyond 90 mg/week have not been described in this population. This case series, derived from a larger study on depression in hemodialysis patients, describes the use of weekly fluoxetine at dosages beyond 90 mg/week.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research